Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).
1 finding from 1 review
Adherence6 · HIV‐negative people at risk of TB infection1
Rifampicin probably leads to higher adherence6 compared with isoniazid (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
1 finding from 1 review
Hepatotoxicity:13 Grade 3 and 4 toxicity · HIV‐negative people at risk of TB infection1
Rifampicin probably leads to lower hepatotoxicity:13 Grade 3 and 4 toxicity compared with isoniazid (moderate certainty).
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus isoniazid changes active TB compared with isoniazid (very low certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus pyrazinamide changes active TB: compared with isoniazid (very low certainty).
1 finding from 1 review
Intervention not reported
ETEC diarrhoea · People travelling from non‐endemic settings
The intervention showed no clear difference in ETEC diarrhoea (low certainty).
1 finding from 1 review
Intervention not reported
Severe ETEC diarrhoea · People travelling from non‐endemic settings
1 finding from 1 review
Intervention not reported
All‐cause diarrhoea · People travelling from non‐endemic settings
The intervention showed no clear difference in all‐cause diarrhoea (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · People travelling from non‐endemic settings
1 finding from 1 review
Intervention not reported
Clinical malaria · Children aged less than 5 years
The intervention leads to lower clinical malaria (high certainty).
1 finding from 1 review
Intervention not reported
Severe malaria · Children aged less than 5 years
The intervention leads to lower severe malaria (high certainty).
1 finding from 1 review
Intervention not reported
Death from any cause · Children aged less than 5 years
The intervention showed no clear difference in death from any cause (moderate certainty).
1 finding from 1 review
Intervention not reported
Moderately severe anaemia · Children aged less than 5 years
The intervention probably leads to lower moderately severe anaemia (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious drug related adverse events · Children aged less than 5 years
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · Children aged less than 5 years
1 finding from 1 review